OncLive TV

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Anna C. Pavlick, DO, discusses how ongoing research efforts at Weill Cornell Medicine are attempting to ameliorate unmet needs in melanoma.

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

David A. Braun, MD, PhD, discusses the enrichment of SLAMF7-positive, CD8-positive T-cells and their role on nivolumab resistance in clear cell and non–clear cell renal cell carcinoma.

Neal Shore, MD, FACS, US discusses the continued evaluation of darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Joyce O’Shaughnessy, MD, discusses the findings from the phase 3 monarchE trial of adjuvant endocrine therapy with or without abemaciclib in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer.

Yi-Bin Chen, MD, discusses key data on the use of vedolizumab in lower gastrointestinal acute Graft-Versus-Host Disease according to the phase 3 GRAPHITE study.

Lori Muffly, MD, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant in older patients with acute myeloid leukemia.

Warren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.

Joanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

Guru P. Sonpavde, MD, discusses the methodology and key results from an analysis of the Cancer Genome Atlas in muscle-invasive bladder cancer.

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Neville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population

Yvonne Chao, MD, PhD, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer.

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.